A clinical trial published in The Lancet suggests that a yearly injection of lenacapavir, developed by Gilead Sciences, is ...

Current health news highlights include Pope Francis returning to ventilation for respiratory issues, Sun Pharma's ...

HumanX, the world's most important AI conference, has announced its return for 2026, with a new location and expanded programming to reflect the industry's rapid evolution. The event's second edition ...

The Association of Related Churches (ARC) is excited to announce the speaker lineup for ARC Conference 2025, taking place April 29?30, 2025, at Milestone Church in Dallas?Fort Worth, Texas. This ...

Sartaba/Alexandrium was built by the Hasmoneans and expanded by Herod. A team of archaeologists has launched a first ...

The location is the company's headquarters for ... let go of an undisclosed number of employees tied to a project with Gilead Sciences’ Kite Pharma. Story Jan. 9 - IGM Biosciences: After ...

A short course of androgen deprivation therapy (ADT) added to stereotactic body radiotherapy (SBRT) halved the risk of ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg. Gilead had the right to ...

In the latest market close, Gilead Sciences (GILD) reached $115.99, with a +1.47% movement compared to the previous day. This move outpaced the S&P 500's daily loss of 1.76%. Meanwhile ...

Weeks after settling a five-year patent dispute with the U.S. government for an undisclosed sum, California's Gilead Sciences revealed that it has set aside $200 million for a potential resolution ...